Triple Treatment Combo Beneficial in BRAF-Mutant CRC
MONDAY, Dec. 28, 2020 -- Irinotecan and cetuximab combined with vemurafenib improve progression-free survival in BRAFV600E-mutated colorectal cancer (CRC), according to a study published online Dec. 23 in the Journal of Clinical Oncology.
Scott Kopetz, M.D., Ph.D., from the University of Texas MD Anderson Cancer Center in Houston, and colleagues randomly assigned 106 patients with BRAFV600E-mutated metastatic CRC previously treated with one or two regimens to receive irinotecan and cetuximab with or without vemurafenib.
The researchers observed improvement in the primary end point of progression-free survival with the addition of vemurafenib (hazard ratio, 0.50). Significant improvements were also seen in the response rate (17 versus 4 percent) and disease control rate (65 versus 21 percent). In 87 versus 0 percent of patients, a decrease in circulating tumor DNA BRAFV600E variant allele frequency was observed, with a low incidence of acquired RAS alterations at the time of progression. Based on RNA profiling, treatment benefit was not dependent on previously established BRAF subgroups or the consensus molecular subtype.
"The addition of vemurafenib to cetuximab and irinotecan represents an active combination that improves progression-free survival," the authors write. "This represents a rationally designed study building on a foundation of understanding of the mechanisms of adaptive resistance in CRC and provides insights for further combination studies in the CRC field in the future."
Several authors disclosed financial ties to biopharmaceutical companies, including Genentech, which manufactures vemurafenib and partially funded the study.
© 2021 HealthDay. All rights reserved.
Posted: December 2020
Read this next
FRIDAY, Jan. 22, 2021 -- There was a significant decrease in the number of patients undergoing screening tests for cancer and in the number of resulting diagnoses of cancerous and...
THURSDAY, Jan. 21, 2021 -- Regular use of aspirin is associated with a reduced risk for colorectal cancer (CRC) among those with initiation of aspirin before age 70 years,...
MONDAY, Jan. 11, 2021 -- Higher body mass index (BMI) is associated with a significantly increased risk for colorectal cancer (CRC) among men, whereas higher waist-to-hip ratio...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.